Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Androgen Deprivation Therapy · 1 trial · 3 indications
Summarized as percentage with 80% two-sided exact binominal confidence interval (CI) for each cohort
| Arm | Type | Description |
|---|---|---|
| COHORT 1: DNA damage repair defects (DDRD) +/- Inflamed Tumor | EXPERIMENTAL | After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial. * Androgen Deprivation Therapy: Given per standard care for duration of study * Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage * Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6. |
| COHORT 2: Inflamed Tumor without DNA repair defects (DDRD) | EXPERIMENTAL | After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial. * Androgen Deprivation Therapy: Given per standard care for duration of study * Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage * Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6. |
| COHORT 3: Biomarker Negative | EXPERIMENTAL | After the screening procedures confirm participation in the research study. The participant will be given a study calendar for this trial. * Androgen Deprivation Therapy: Given per standard care for duration of study * Nivolumab: Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage * Docetaxel: Given once every 3 weeks intravenously at pre-determined dosage for cycle 1-6 |
| Name | Type | Description |
|---|---|---|
| Androgen Deprivation Therapy | DRUG | Given per standard care for duration of study. Regimens include Leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care. |
| Nivolumab | DRUG | Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total. |
| Docetaxel | DRUG | Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6. |
Inclusion Criteria: * Newly diagnosed histologically confirmed prostate adenocarcinoma within 6 months prior to study registration with evidence of high-volume distant metastasis on conventional imaging * Distant metastasis is defined by non-regional lymph node(s) metastasis (M1a), bone metastasis ...
Androgen Deprivation Therapy is used for Hormone Sensitive Prostate Cancer, including prostate adenocarcinoma and metastatic prostate adenocarcinoma. It is being studied in combination with other agents in a clinical trial for patients with these conditions.
Androgen Deprivation Therapy is being developed by Bristol-Myers Squibb Company, traded on the stock exchange under the ticker BMY. The company is conducting a Phase 2 clinical trial for this therapy in Hormone Sensitive Prostate Cancer.
Androgen Deprivation Therapy is in Phase 2 clinical development. It is an investigational therapy for Hormone Sensitive Prostate Cancer and is not yet approved by regulatory authorities. The ongoing trial is active but not recruiting participants.
Androgen Deprivation Therapy is being studied in the clinical trial NCT04126070, titled 'Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors'. This Phase 2 trial is active but not recruiting, with an enrollment of 47 participants in the United States.
Yes, Androgen Deprivation Therapy is classified as a small molecule modality. It is being evaluated in the oncology therapeutic area for the treatment of Hormone Sensitive Prostate Cancer.